Sunesis Pharmaceuticals (NASDAQ:SNSS) – Cantor Fitzgerald issued their FY2018 earnings per share (EPS) estimates for shares of Sunesis Pharmaceuticals in a research note issued to investors on Sunday, March 11th, according to Zacks Investment Research. Cantor Fitzgerald analyst M. Goldstein forecasts that the biopharmaceutical company will post earnings per share of ($1.08) for the year. Cantor Fitzgerald currently has a “Hold” rating and a $4.00 target price on the stock.
A number of other equities research analysts have also recently issued reports on SNSS. Wells Fargo raised shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their target price for the company from $2.86 to $2.48 in a report on Monday, December 11th. Oppenheimer initiated coverage on shares of Sunesis Pharmaceuticals in a report on Thursday, December 14th. They issued a “buy” rating and a $7.00 target price on the stock. ValuEngine raised shares of Sunesis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th. Finally, Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $4.00.
Shares of Sunesis Pharmaceuticals stock traded down $0.11 during trading hours on Wednesday, reaching $2.48. 154,911 shares of the company’s stock were exchanged, compared to its average volume of 302,261. The company has a market cap of $93.77, a price-to-earnings ratio of -1.71 and a beta of 1.81. Sunesis Pharmaceuticals has a fifty-two week low of $1.82 and a fifty-two week high of $7.69.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.08.
Several hedge funds have recently modified their holdings of SNSS. Vatera Holdings LLC bought a new stake in shares of Sunesis Pharmaceuticals in the 4th quarter valued at about $673,000. Geode Capital Management LLC raised its holdings in Sunesis Pharmaceuticals by 105.2% in the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 64,343 shares during the period. Wells Fargo & Company MN raised its holdings in Sunesis Pharmaceuticals by 127.6% in the 3rd quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 53,396 shares during the period. Vanguard Group Inc. raised its holdings in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after acquiring an additional 23,819 shares during the period. Finally, BlackRock Inc. raised its holdings in Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock valued at $482,000 after acquiring an additional 11,351 shares during the period. 53.04% of the stock is currently owned by institutional investors.
WARNING: “Analysts Offer Predictions for Sunesis Pharmaceuticals’ FY2018 Earnings (SNSS)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/sunesis-pharmaceuticals-inc-snss-to-post-fy2018-earnings-of-1-08-per-share-cantor-fitzgerald-forecasts.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML).
Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.